MedPath

Bimatoprost

These highlights do not include all the information needed to use BIMATOPROST OPHTHALMIC SOLUTION safely and effectively. See full prescribing information for BIMATOPROST OPHTHALMIC SOLUTION. BIMATOPROST ophthalmic solution, 0.03% for topical ophthalmic use              Initial U.S. Approval: 2001

Approved
Approval ID

a4f4ecb2-999f-4656-8f94-2f06c6dd7990

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Aug 25, 2023

Manufacturers
FDA

Alembic Pharmaceuticals Inc.

DUNS: 079288842

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Bimatoprost

PRODUCT DETAILS

NDC Product Code62332-507
Application NumberANDA210263
Marketing CategoryC73584
Route of AdministrationOPHTHALMIC
Effective DateMarch 24, 2021
Generic NameBimatoprost

INGREDIENTS (7)

BIMATOPROSTActive
Quantity: 0.3 mg in 1 mL
Code: QXS94885MZ
Classification: ACTIB
SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATEInactive
Code: 70WT22SF4B
Classification: IACT
SODIUM CHLORIDEInactive
Code: 451W47IQ8X
Classification: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: IACT
BENZALKONIUM CHLORIDEInactive
Code: F5UM2KM3W7
Classification: IACT
CITRIC ACID MONOHYDRATEInactive
Code: 2968PHW8QP
Classification: IACT
HYDROCHLORIC ACIDInactive
Code: QTT17582CB
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Bimatoprost - FDA Drug Approval Details